Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant

Andrew I. G. McLennan, Reanne Booker, Cameron Roessner and Marc Kerba ()
Additional contact information
Andrew I. G. McLennan: Department of Psychology, University of Regina, Regina, SK S4S 0A2, Canada
Reanne Booker: Palliative Care, Arthur J.E. Child Comprehensive Cancer Centre, Alberta Health Services, Calgary, AB T2N 4N2, Canada
Cameron Roessner: Pharmacy Services, Arthur J.E. Child Comprehensive Cancer Centre, Alberta Health Services, Calgary, AB T2N 4N2, Canada
Marc Kerba: Department of Radiation Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada

IJERPH, 2025, vol. 22, issue 7, 1-15

Abstract: Cancer patients use cannabis for medicinal purposes; however, few studies have examined hematology patients’ use of cannabis and no research to our knowledge has investigated the use of cannabis amongst hematology patients before and after hematopoietic stem cell transplant (HCT). The purpose of this longitudinal survey study was to assess aspects of cannabis use in patients who underwent HCT. Eligible patients ( N = 30) completed two surveys before and 90 days following their HCT. The surveys inquired about several aspects of cannabis (e.g., rate of use, beliefs and attitudes, access to information) and physical and psychological outcomes (e.g., anxiety, comorbidities, graft-versus-host-disease). Rates of cannabis use decreased following HCT ( n = 14, 46% to n = 11, 40%). Conversations on cannabis that were initiated by an oncology health care provider increased post-transplant ( n = 3, 10% to n = 11, 37%). This coincided with fewer who were smoking cannabis as a primary consumption method ( n = 5, 38 to n = 2, 18) and an increase in the use of pharmaceutical cannabinoid products ( n = 4, 13% to n = 6, 21%) as well as oils and topicals. Of the total sample, 63% ( n = 17) experienced post-treatment complications and 33% ( n = 10) developed GVHD, six of whom where recent cannabis users. This study provided insight into cannabis use amongst HCT patients and warrants further research with this population, including more exploration of the relationship between GVHD and cannabis.

Keywords: cannabis; THC; CBD; leukemia; lymphoma; bone-marrow-transplant; alternative therapies; graft-versus-host-disease (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/22/7/990/pdf (application/pdf)
https://www.mdpi.com/1660-4601/22/7/990/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:22:y:2025:i:7:p:990-:d:1685666

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().